Published
MHRA vs FDA vs EMA — Peptide Regulatory Comparison 2026
How the UK MHRA, US FDA and EU EMA each classify and regulate research-grade peptides in 2026. Approval pathways, enforcement priorities, import rules.
Research peptides are regulated under three distinct legal frameworks in the UK, United States, and European Union. These frameworks share a common purpose — ensuring that substances presented as medicines are safe and effective — but differ substantially in their classification criteria, enforcement priorities, and the regulatory status they assign to specific compounds. This article compares the three frameworks as they apply to the research-peptide landscape in 2026.
The foundational legal test
All three frameworks apply a version of the same foundational test: does this substance constitute a medicine? A substance that is held out as treating, preventing, or diagnosing disease is regulated as a medicine and requires marketing authorisation before it can be sold or administered. A substance supplied strictly for in vitro laboratory research, without any therapeutic claim, generally falls outside the medicinal product definition — though the boundary is actively policed.
The practical implication is that regulatory status is not fixed solely by the chemistry of the compound. The same peptide molecule can be:
- A licensed medicine (if approved and sold as such by an authorised manufacturer)
- A research chemical (if sold to laboratories with documented research use and no therapeutic claims)
- An unlicensed medicinal product (if sold with implied or explicit therapeutic claims without authorisation) — which is a criminal offence in all three jurisdictions
MHRA — UK
Legal framework
The MHRA (Medicines and Healthcare products Regulatory Agency) administers UK medicines law under the Human Medicines Regulations 2012 (as amended post-Brexit). Following the UK's departure from the EU, the MHRA operates independently of the EMA and has developed its own registration pathway (the UKMA — UK Marketing Authorisation), though historical EMA authorisations were grandfathered at Brexit and remain valid in the UK where not withdrawn.
Position on unapproved research peptides
The MHRA's position on research-grade peptides with no UK marketing authorisation is set out in guidance that distinguishes between:
- Supply for genuine laboratory research — permissible where the supplier is an authorised wholesale dealer or the end-user is a research institution, there are no therapeutic claims, and the substance is not presented as fit for human use
- Supply with implied or explicit human-use claims — a potential criminal offence under Regulation 46 of the Human Medicines Regulations 2012 regardless of whether the substance has therapeutic merit
Special Authorisation (Specials)
The UK's Special Authorisation pathway (sometimes called "Specials" manufacturing) allows licensed specials manufacturers to supply unlicensed medicines to specific named patients under a prescriber's direction where no licensed equivalent is available. This pathway is the legal mechanism by which Cerebrolysin can be supplied in the UK: a prescriber can request it through a licensed specials importer, with the MHRA's oversight, for a named patient. This is not a general-availability pathway — it requires a licensed specials dealer (holder of an MHRA Manufacturer's Specials licence or Wholesale Dealer's Authorisation with specials permission) at each step.
Enforcement priorities 2024–2026
The MHRA's 2024–2025 enforcement programme included a sustained operation targeting online suppliers of unapproved peptides and injectables sold with human-use marketing. Published enforcement actions during this period included:
- Prosecutions and civil seizures targeting Melanotan II suppliers making explicit tanning and skin-darkening claims to consumers — Melanotan II has been an MHRA enforcement priority since approximately 2008, and supply with human-use claims has been the subject of multiple successful prosecutions
- Increased scrutiny of GLP-1 agonist analogues supplied as "research grade" through e-commerce platforms, following the surge in consumer demand for semaglutide and Tirzepatide driven by weight-loss publicity. The MHRA noted in 2024 guidance that compounded or research-grade GLP-1 agonists sold to consumers do not meet the standards of the licensed medicines and carry quality and safety risks
- Warning letters to supplement and sports-nutrition retailers who had begun marketing BPC-157 and TB-500 products with recovery and tissue-repair claims directed at athletes
Import rules
Importing unapproved medicinal products for personal use into the UK is not a defined legal exemption in UK law (unlike in some other jurisdictions). The MHRA's enforcement priority is commercial supply rather than individual importation, but importers cannot rely on a formal personal-use exemption.
FDA — United States
Legal framework
The FDA regulates medicines under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The relevant classification for research peptides is the distinction between:
- FDA-approved drugs — holding a New Drug Application (NDA) or Biologics Licence Application (BLA)
- Investigational drugs — under an active Investigational New Drug (IND) application, permissible for use only within the approved clinical trial protocol
- Research chemicals — not regulated as drugs if sold strictly for laboratory research with no human-use claims; regulated as drugs if human-use claims are made
USP-grade vs research-grade
The United States Pharmacopeia (USP) sets quality standards for medicines sold in the US market. A peptide supplied to a research laboratory is not required to meet USP standards; a peptide incorporated into a compounded medicine dispensed to patients must. The research-grade vs compounded-medicine distinction is therefore significant in the US context: research-grade material sold to laboratories for in vitro use is distinct from compounded versions of FDA-approved drugs dispensed by 503A or 503B compounders.
The FDA's 2023–2024 enforcement actions in this area focused substantially on 503A and 503B compounders supplying semaglutide and Tirzepatide during the nationwide drug shortage of those branded products. The FDA's position was that compounding an FDA-approved drug whose branded version is not in shortage is impermissible; compounding during shortage periods operates under a distinct set of enforcement discretion policies.
Personal importation policy
The FDA maintains an informal personal importation policy (FDA Regulatory Procedures Manual chapter 9-71) under which it generally exercises enforcement discretion for individuals importing a 3-month supply of an unapproved medicine for personal use, provided the product appears to be for personal use, is not commercialised, and does not present an unreasonable risk. This is discretionary, not a legal right, and is narrower in scope than often characterised in research-peptide forums.
EMA — European Union
Legal framework
The EMA (European Medicines Agency) is the EU-level agency that assesses and recommends marketing authorisations for the EU market under Regulation (EC) No 726/2004 (centralised procedure) and the associated national procedures. Individual EU member states retain competence for national authorisation of certain product categories and for enforcement.
Article 5(1) Special Authorisation
Article 5(1) of Directive 2001/83/EC allows member states to supply an unlicensed medicinal product to fulfil a special-needs request from a licensed healthcare professional, where no suitable licensed product is available for a named patient. This is the EU equivalent of the UK's Specials mechanism. Cerebrolysin, which has marketing authorisation in Austria (Ebewe Pharma), Russia, and several other jurisdictions, can be accessed in some EU member states under Article 5(1) by a physician making a documented special-needs case.
Compound-specific examples in EU
Tirzepatide (Mounjaro) received EMA marketing authorisation in September 2023 for type 2 diabetes management; Zepbound (obesity indication) received EMA approval in March 2024. It is therefore a POM in all EU jurisdictions for those indications, and research-grade equivalents supplied with human-use claims would constitute supply of an unlicensed medicinal product in EU member states.
Retatrutide has not received EMA marketing authorisation as of 2026 and remains an investigational compound within the Eli Lilly TRIUMPH Phase III programme. Supply of Retatrutide outside a clinical trial context, with implied therapeutic claims, would constitute supply of an unlicensed medicine in all EU jurisdictions.
Compound-by-compound regulatory summary
| Compound | MHRA (UK) | FDA (USA) | EMA / EU |
|---|---|---|---|
| Tirzepatide | Licensed POM (Mounjaro / Zepbound) | Licensed (NDA: Mounjaro, Zepbound) | Licensed (Mounjaro, Zepbound) |
| Semaglutide | Licensed POM (Ozempic / Wegovy) | Licensed (Ozempic, Wegovy) | Licensed (Ozempic, Wegovy) |
| Retatrutide | Unapproved; Phase III investigational | Unapproved; Phase III IND | Unapproved; Phase III investigational |
| BPC-157 | No authorisation; research use only | No NDA; research use only | No authorisation; research use only |
| Cerebrolysin | No UK MA; Special Authorisation required | No NDA; unapproved | National MAs in select EU states; Art. 5(1) elsewhere |
| Epitalon | No authorisation anywhere | No authorisation | No authorisation; isolated Russian registration |
| TB-500 | No authorisation; research use only | No authorisation; research use only | No authorisation; research use only |
What this means for UK researchers
For UK-based researchers, the practical position as of 2026 is:
- Licensed compounds (Tirzepatide, semaglutide) require a prescription and must be dispensed from a licensed pharmacy. Research-grade equivalents from non-pharmacy suppliers remain in a grey zone and are subject to increased MHRA scrutiny.
- Unapproved compounds (BPC-157, TB-500, Epitalon, TB-500, GHK-Cu, Semax, Selank) are permissible for documented in vitro laboratory research. Human administration is unlawful under UK medicines law outside an approved clinical trial.
- Special Authorisation compounds (Cerebrolysin in the UK) require an MHRA-licensed specials importer and a supervising prescriber — they are not available through research-chemical channels.
The regulatory position is evolving rapidly. The metabolic peptide class in particular has attracted sustained enforcement attention from all three agencies in 2024–2026, driven by consumer demand and supply-chain pressures. Before procuring any peptide compound, verifying the current MHRA status at mhra.gov.uk is advisable.
The companion article UK Peptide Regulation 2026 covers the MHRA position in greater depth for UK researchers. For per-compound regulatory notes and supply chain guidance for each peptide discussed on this site, PeptideAuthority.co.uk maintains individual compound monographs with current regulatory status across UK, US, and EU jurisdictions. The Tirzepatide + Retatrutide + AOD-9604 metabolic stack page also includes a regulatory-context section specific to that combination.